Pirfenidone ameliorates MAFLD by improving insulin sensitivity and reducing epididymal fat
Introduction and Objectives: Metabolic associated fatty liver disease (MAFLD) is characterized by hepatic steatosis with the following three metabolic conditions: obesity/overweight, diabetes and metabolic dysregulation, either alone or in combination. Pirfenidone (PFD) has anti-inflammatory, antiox...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-12-01
|
| Series: | Annals of Hepatology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268122002022 |